This transaction
Establishment of SubsidiariesThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
Development, manufacture and sale of scientific products and products for experiments and research Provision of services related to the above products
Immaterial
| Item | Details |
|---|---|
| Transaction name | Establishment of Subsidiaries |
| Name of the Subject Company | Japan Tissue Engineering Europe GmbH |
| Business Description of the Subject Company | Development, manufacture and sale of scientific products and products for experiments and research Provision of services related to the above products |
| Location of the Subject Company | Federal Republic of Germany (Heidelberg) |
| Capital Stock of the Subject Company | €25,000 (approximately ¥4.6 million) |
| Voting rights ownership percentage | After 100% (before not disclosed) |
| Impact on Business Performance | Immaterial |
| Date of board resolution | 19 June 2026 |
| Management structure after acquisition | The representative will be Director Ninagawa Yoshihide (蜷川 欣秀), an executive officer of the Company. One of the Company's executive officers will concurrently serve as the representative of the subsidiary. |
Items this document does not state (23)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The LabCyte Series of human tissues cultured for research use has a short shelf life, and transportation and storage constraints had made stable supply to Europe difficult amid growing geopolitical instability. The Company therefore determined that a local manufacturing and sales structure was essential. Germany offers logistical advantages, and the Company expects to be able to establish production operations quickly while limiting initial investment through a partnership with a shared laboratory.